Qsymia Approval History
- FDA approved: Yes (First approved July 17th, 2012)
- Brand name: Qsymia
- Generic name: phentermine and topiramate
- Dosage form: Extended-Release Capsules
- Previous name: Qnexa
- Company: Vivus, Inc.
- Treatment for: Obesity
Qsymia (phentermine and topiramate) is a combination of phentermine, a sympathomimetic amine anorectic, and topiramate extended-release, an antiepileptic drug, indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults.
Development History and FDA Approval Process for Qsymia
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.